Recently, modification of the gut flora by supplementation with prebiotics has been considered to be a potential therapeutic strategy to reduce uremic toxins of intestinal origin and inflammation
Both PAD and tTG are active in joints and the intestine, with the latter of these modification proteins being over expressed in the synovium of RA patients suggesting a possible role in disease pathogenesis (Lauzier et al
Lactoferrin protects against iron dysregulation, oxidative stress, and apoptosis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease in mice
Their latest work explores whether targeted biological therapies have the potential to effectively treat fetal growth restriction (FGR)
The natural levels of glutathione decline with age, stress, a poor diet, and exposure to environmental toxins
Interpreting results and measuring success Defining success: Stability (no progression) often represents success for chronic degenerative diseases